HomeMy WebLinkAbout2025-09-08 25-265 Order *��a�$qti�a CITY COUNCIL ACTION
/
!,�/' 1�,, Council Meeting Date: 09/08/2025
If��-' �'� Item No: 25-265
_ - _ . -,,�,
`�n�= �
'��A����ti Responsible Dept: Legal
ren,�
Requested Action: Order Map/Lot: N/A
Title, Order
Authorizing the City Manager and City Solicitor to Execute Settlement Documents in the Multi-District Opioid
Litigation, Including Settlements with Eight Small Pharmaceutical Manufacturers
Summary
This Order would authorize the City Manager and City Solicitor to take any action necessary to effectuate
settlement agreements in the multi-district opioid litigation cases, including agreements with the State
regarding apportionment of funds, and including opting in on the City's behalf to participate in the
settlement agreements reached with the small pharmaceutical manufacturers.
The State of Maine, along with many other states, has reached settlements in the opioid litigation matters
against the eight small pharmaceutical manufacturers listed above. These settlements will collectively add
up to an additional $1.1 billion in cash and pharmaceutical product to be distributed among state and local
governments across the country. The details of the settlements available online.
The settlement group will use the same allocation formula as was used with the prior national settlement
agreements in this litigation. The State of Maine and the local governments will receive the same
proportional share of the settlements as they received with respect to the past settlements.
The settlements also contain injunctive relief governing opioid marketing, sale, and distribution practices,
including requiring these eight manufacturers to implement safeguards to prevent diversion of prescription
opioids. The opioid marketing and suspicious monitoring programs will be overseen by the States.
Funds received by the City under these settlements would be used to combat the opioid crisis, thereby
improving and preserving the health and safety of Bangor's citizens.
Committee Action
Committee: Meeting Date:
Action: Recommend for passage For: Against:
Staff Comments &Approvals
Staff recommends approval.
���� ���� �
City Manager City Solicitor Finance Director
Introduced for: New Business
�-art_aa;y�� CITY OF BANGOR ORDER
c�*�'; ,°�+
i%�m��;� ��m Date: 09/08/2025
f��.
,n�_:-.... _.=�;M
�,v�. .� Item No: 25-265
'AJ°�'�`�� �`4
°Rar�n,��-�� Assigned to Councilor: Fish
Authorizing the City Manager and City Solicitor to Execute Settlement Documents in the Multi-District Opioid
Litigation, Including Settlements with Eight Small Pharmaceutical Manufacturers
Whereas, the State of Maine, along with many other states, has signed on in favor of settlement agreements
in the opioid litigation that would settle the cases against the small pharmaceutical manufacturers Alvogen,
Inc., Amneal Pharmaceuticals, Inc., Apotex Inc., Hikma Pharmaceuticals USA Inc., Invidior Inc., Mylan
Pharmaceuticals Inc., Sun Pharmaceutical Industries, Inc., and Zydus Pharmaceuticals (USA), Inc.; and
Whereas, these settlements will collectively add up to an additional $1.1 billion in cash and pharmaceutical
product to be distributed among state and local governments across the country; and
Whereas, the details of the settlements are outlined here: https://nationalopioidsettlement.com/; and
Whereas, funds received by the City under these settlements would be used to combat the opioid crisis,
thereby improving and preserving the health and safety of Bangor's citizens; and
Whereas, the Ciry wishes to authorize the City Manager and the City Solicitor to execute settlement
documents on the City's behalf in the multi-district opioid litigation.
Be it Ordered by the City Council of the City of Bangor, that the City Manager and City Solicitor are authorized
to take any action necessary to effectuate settlement agreements in the pending multi-district opioid litigation,
including but not limited to opting in on behalf of the City to participate in the settlements with Alvogen, Inc.,
Amneal Pharmaceuticals, Inc., Apotex Inc., Hikma Pharmaceuticals USA Inc., Invidior Inc., Mylan
Pharmaceuticals Inc., Sun Pharmaceutical Industries, Inc., and Zydus Pharmaceuticals (USA), Inc., and
including agreements with the State regarding apportionment of funds.
IN CITY COUNCIL
SEPTEMBER 8, 2025
CO 25-265
Motion made and seconded for Passage
Passed
�
DEPUTY CITY CLERK